Form 4 for BIIB Biogen
Accepted 2024-02-13 00:00:00 ET · period of report 2024-02-09 · accession 0001127602-24-004800 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-02-13 | 2024-02-09 | BIIB | Murphy Nicole | Head of Pharm Ops, Tech | M - OptEx | $0.00 | +2,272 | 9,529 | +31% | $0 |
| D | 2024-02-13 | 2024-02-09 | BIIB | Murphy Nicole | Head of Pharm Ops, Tech | F - Tax | $240.98 | -761 | 8,768 | -8% | -$183.4K |
| D | 2024-02-13 | 2024-02-09 | BIIB | Murphy Nicole | Head of Pharm Ops, Tech | M - OptEx | $0.00 | -2,272 | 2,272 | -50% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-02-09 | M | A | 2,272 | $0.00 | 9,528.99 | D | — | — | |
| 2 | Common | Common Stock | 2024-02-09 | F | D | 761 | $240.98 | 8,767.99 | D | — | — | |
| 3 | Derivative | Restricted Stock Unit | 2024-02-09 | M | D | 2,272 | $0.00 | 2,272 | D | $0.00 · — to 2025-02-10 | 2,272 Common Stock | (F1) The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 10, 2022. |